TABLE 2.
Results of a primary meta‐analysis.
| MADRS (SMD [95% CI]) | ||
| ARI | −0.081 (−0.282, 0.120) | −0.305 (−0.434, −0.176) |
| BRE | −0.224 (−0.378, −0.070) | |
| PLA | ||
| Non‐response rate (OR [95% CI]) | ||
| ARI | 0.817 (0.510, 1.309) | 0.574 (0.434, 0.758) |
| BRE | 0.702 (0.480, 1.027) | |
| PLA | ||
| Non‐remission rate (OR [95% CI]) | ||
| ARI | 0.795 (0.468, 1.350) | 0.583 (0.430, 0.790) |
| BRE | 0.733 (0.475, 1.132) | |
| PLA | ||
| CGI‐S (SMD [95% CI]) | ||
| ARI | 0.030 (−0.171, 0.230) | −0.162 (−0.290, −0.033) |
| BRE | −0.191 (−0.345, −0.037) | |
| PLA | ||
| Social function (SMD [95% CI]) | ||
| ARI | −0.157 (−0.393, 0.079) | −0.427 (−0.575, −0.279) |
| BRE | −0.270 (−0.454, −0.086) | |
| PLA | ||
| All‐cause discontinuation (OR [95% CI]) | ||
| ARI | 0.617 (0.185, 2.063) | 1.018 (0.503, 2.060) |
| BRE | 1.650 (0.619, 4.396) | |
| PLA | ||
| Discontinuation because of adverse events (OR [95% CI]) | ||
| ARI | 0.760 (0.155, 3.724) | 2.700 (0.975, 7.478) |
| BRE | 3.552 (1.049, 12.025) | |
| PLA | ||
| At least one adverse event (OR [95% CI]) | ||
| ARI | 1.131 (0.652, 1.962) | 1.665 (1.186, 2.339) |
| BRE | 1.472 (0.954, 2.271) | |
| PLA | ||
| Serious adverse event (OR [95% CI]) | ||
| ARI | 0.428 (0.054, 3.390) | 0.634 (0.172, 2.334) |
| BRE | 1.482 (0.297, 7.395) | |
| PLA | ||
| Akathisia (OR [95% CI]) | ||
| ARI | 0.416 (0.104, 1.657) | 5.948 (3.171, 11.158) |
| BRE | 14.311 (4.177, 49.024) | |
| PLA | ||
| Tremor (OR [95% CI]) | ||
| ARI | 1.229 (0.162, 9.306) | 1.920 (0.578, 6.371) |
| BRE | 1.562 (0.306, 7.980) | |
| PLA | ||
| Weight gain (OR [95% CI]) | ||
| ARI | 2.455 (0.625, 9.639) | 7.850 (2.748, 22.426) |
| BRE | 3.198 (1.331, 7.684) | |
| PLA | ||
Note: Drugs are reported alphabetically. Data are presented as odds ratios or standardized mean differences (95% confidence intervals) in the column‐defining treatment compared with the row‐defining treatment. Odds ratios <1 favor the row‐defining treatment. Standardized mean differences <0 favor the row‐defining treatment.
The boldface result indicates statistical significance.
Abbreviations: 95% CI, 95% confidence interval; ARI, aripiprazole; BRE, brexpiprazole; CGI‐S, Clinical Global Impression of illness Severity; MADRS, Montgomery Åsberg Depression Rating Scale; OR, odds ratio; PLA, placebo; SMD, standardized mean difference.